Investing Experience -
Risk Profile -
Followers
0
Following
2
Blog Posts
0
Threads
16,722
Blogs
Threads
Portfolio
Follower
Following
Summary
Total comments
16,722
Past 30 days
0
Past 7 days
0
Today
0
User Comments
Stock
2020-11-24 08:39 | Report Abuse
let's durian do vaccine.. new generation..
Stock
2020-11-24 07:32 | Report Abuse
I like down buy, up buy, anytime I like to buy...
Stock
2020-11-24 07:32 | Report Abuse
aiya.. I come here just do investment only..
Stock
2020-11-23 23:32 | Report Abuse
down buy buy, up also buy, everywhere keep buy...
Stock
2020-11-23 23:31 | Report Abuse
then wait Wat, tomorrow show time liao...
Stock
Stock
2020-11-23 21:50 | Report Abuse
let's 10000% work smoothly..
Stock
Stock
Stock
Stock
2020-11-23 18:33 | Report Abuse
yes sad too.. how to getting out pn17? rili big problem..
Stock
2020-11-23 17:34 | Report Abuse
thanks de info bulldog.. Im also believe tat 2nd wave coming for real..
Stock
2020-11-23 17:00 | Report Abuse
pray for the best.. come come
Stock
2020-11-23 16:59 | Report Abuse
yalo.. last year I'm here. can said earn 4 times? aiya.. investment only..
Stock
2020-11-23 16:50 | Report Abuse
haha.. this year how calculate could tear give 0.30 cents. how trap high oh.. huhuhu...
Stock
2020-11-23 16:30 | Report Abuse
down buy buy, up buy buy, everywhere buy buy....
Stock
2020-11-23 16:30 | Report Abuse
ya how up without u buy.. aduh..
Stock
2020-11-23 16:14 | Report Abuse
OK OK... behind huat ah....
Stock
Stock
Stock
Stock
2020-11-23 15:13 | Report Abuse
yeah ur hope will come true..
Stock
2020-11-23 15:07 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock
Stock
Stock
2020-11-23 15:05 | Report Abuse
yes winner patient.. patient winner..
Stock
Stock
2020-11-23 14:40 | Report Abuse
big volume coming eating....
Stock
Stock
Stock
2020-11-23 14:34 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock
2020-11-23 14:27 | Report Abuse
good news for everyone.... up up
Stock
Stock
Stock
2020-11-23 14:24 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock
Stock
2020-11-23 14:21 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock
Stock
2020-11-23 14:20 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock
Stock
2020-11-23 14:20 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock
Stock
2020-11-23 14:19 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock
Stock
2020-11-23 14:19 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock
Stock
2020-11-23 14:18 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock
Stock
2020-11-23 14:18 | Report Abuse
Reference is made to Kanger’s announcement on 29 September 2020 (ref no. GA1-29092020-00043) whereby the Group had entered into a three-year collaboration agreement with Sinopharm Group Hunan Changde Medical Co Ltd for the distribution of Covid-19 vaccines and medical equipment in Malaysia which are developed by China National Pharmaceutical Group Corporation (“Sinopharm”).
The Board of Directors of Kanger is pleased to announce that National Institutes of Biotechnology Malaysia (“NIBM”), an agency under the Ministry of Science, Technology and Innovation Malaysia has issued a letter which states that NIBM has no objections for Kanger to communicate with the relevant stakeholders at Sinopharm to purchase Covid-19 vaccines for private sector use in Malaysia.
Stock: [TOPGLOV]: TOP GLOVE CORPORATION BHD
2020-11-24 08:46 | Report Abuse
yeah glove very good